Radboud University Medical Center, Drug Discovery Factory and Specs announced the establishment of ONCODRONE BV, a company dedicated to develop life-prolonging therapeutics for advanced cancer. Dr. Henk Viëtor (CEO) and Prof. dr. Jack Schalken (CSO) will lead the company, which is ready for regulatory drug development for advanced prostate cancer. The establishment of ONCODRONE BV was supported by a ZonMW/NGI Pre-Seed grant.
News release: ONCODRONE company established by Radboud University Medical Center, Drug Discovery Factory and Specs – November 27, 2013  – Nijmegen, The Netherlands